Neurocrine Biosciences, Inc [NBIX] stock is trading at $139.6, up 0.48%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NBIX shares have gain 3.08% over the last week, with a monthly amount glided 8.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurocrine Biosciences, Inc [NASDAQ: NBIX] stock has seen the most recent analyst activity on July 21, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $163. Previously, Goldman started tracking the stock with Buy rating on July 10, 2025, and set its price target to $182. On April 15, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $138 on the stock. RBC Capital Mkts upgraded its rating to a Outperform but stick to its price target of $137 on April 14, 2025. Deutsche Bank initiated its recommendation with a Hold and recommended $138 as its price target on February 11, 2025. In a note dated August 29, 2024, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $131 to $159.
Neurocrine Biosciences, Inc [NBIX] stock has fluctuated between $84.23 and $154.61 over the past year. Currently, Wall Street analysts expect the stock to reach $162.75 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $139.6 at the most recent close of the market. An investor can expect a potential return of 16.58% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Neurocrine Biosciences, Inc [NASDAQ:NBIX] reported sales of 2.51B for the trailing twelve months, which represents a growth of 16.49%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.21%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.13 and Total Capital is 0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 138.44 points at the first support level, and at 137.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 140.40, and for the 2nd resistance point, it is at 141.19.
Ratios To Look Out For
For context, Neurocrine Biosciences, Inc’s Current Ratio is 3.20. As well, the Quick Ratio is 3.10, while the Cash Ratio is 0.48. Considering the valuation of this stock, the price to sales ratio is 5.52, the price to book ratio is 5.13 and price to earnings (TTM) ratio is 41.21.
Transactions by insiders
Recent insider trading involved GORMAN KEVIN CHARLES, Director, that happened on Aug 07 ’25 when 0.11 million shares were sold. Director, KEVIN CHARLES GORMAN completed a deal on Aug 07 ’25 to buy 0.11 million shares. Meanwhile, Chief Regulatory Officer Delaet Ingrid sold 457.0 shares on Jul 10 ’25.
